About the Video
MAIA Biotechnology has developed THIO, a new molecule that targets telomeres that are present in 85% of cancer cells. It kills 70-90% of the cancer cells in under 72 hours. When used with a checkpoint inhibitor, it leads to a complete response with no recurrence.
Join our webinar with MAIA founder and CEO, Dr. Vlad Vitoc, to learn more about their treatment and why Regeneron has partnered with them on a recent Phase 2 trial.